PK/PD Flashcards

1
Q

what is PK/PD modelling

A

data driven analyses based on statistical and mathemetical models.
investigate the relationship between the concentration of a drug (pharmacokinetics, PK) and its pharmacological effect (pharmacodynamics, PD).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are in silico experiments

A

experimentations performed by computers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what do PK/PD graphs include

A

pk: conc. vs time
PD: effect vs conc
pk/pd: effect vs time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what does PK/PD include

A

experiments that involve conc, effect, time using design, analysis modelling and simulations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are the benefits of PK/PD studies

A
  1. relate in vivo to in vitro data
  2. translate animal models to humans
  3. explain variabilities in responses
  4. aid dose and regimen selection
  5. identify and increase confidence in biomarkers
  6. understand time course of response, relationship between dose and response, tolerance and sensitization.

These studies provide valuable information about how drugs interact with the body, how their concentrations change over time, and how these changes relate to the observed therapeutic or toxic effects.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the three pillars that improve chances of progressing into phase 3 clinical trials.

A
  1. exposure at target site of action
  2. binding to target
  3. expression of functional activity.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what does pop-pk focus on

A

identifying causes of variability in pK within a population group
used to determine optimum safe dosing strategies for sub groups

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what causes Pk variability in populations

A

(extent and rates of ADME)
differences in vd (due to weight or protein binding)
differences in bioavailability and absorption rate
and differences in CL due to renal and hepatic function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what causes Pd variability in populations

A

(relationship between drug conc and effect)
differences in receptor number, affinity, endogenous substances, effects of disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are some differences between classical and population Pk studies

A

classical: healthy volunteers, small size, dense 1-6 time points, inter individual variability minimized (main focus is on characterizing the drug’s ADME)
population: non healthy volunteers, large or integrated size, few samples for many patients. ( aim to characterize the PK of a drug in a broader population)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the aim of PKPB modelling

A

physiology based pk modelling describes the PK of pharmaceuticals within different organs and tissues
is a form of mechanistic modelling (aims to stimulate complex mechanisms)
used in DDI interaction studies, pharmacogenetics, PK in special populations, first in human dose predictions,
effect of changes in physiology and biochem on PK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what do PKPB models require

A

system data on organ perfusion, organ volume, body weight, fat content, enzyme transporter and plasma protein abundance. (physiological and biochemical data)

compound data
pKa Fu MW CLint KM VMAX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what leads to different PK/PD outcomes

A

process/system noise, assumption that individuals have random fluctuations
stochastic modelling is used where randomness or uncertainty plays a fundamental role

How well did you know this?
1
Not at all
2
3
4
5
Perfectly